GlobeNewswire: ExCellThera Contains the last 10 of 27 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:09:15ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/01/02/2802574/0/en/ExCellThera-to-Conduct-Investor-Meetings-During-the-J-P-Morgan-42nd-Annual-Healthcare-Conference-and-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=48969ExCellThera to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference and to Participate in Upcoming Investor Conferences2024-01-02T12:00:20Z<![CDATA[MONTREAL, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell therapies, announced today that its senior leaders will be holding investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, in San Francisco, CA, and will be participating in the following investor conferences in January:]]>https://www.globenewswire.com/news-release/2024/01/02/2802574/0/fr/ExCellThera-rencontrera-les-investisseurs-durant-la-42e-conf%C3%A9rence-annuelle-J-P-Morgan-Healthcare-et-participera-aux-prochaines-conf%C3%A9rences-d-investisseurs.html?f=22&fvtc=4&fvtv=48969ExCellThera rencontrera les investisseurs durant la 42e conférence annuelle J.P. Morgan Healthcare et participera aux prochaines conférences d'investisseurs2024-01-02T12:00:20Z<![CDATA[MONTREAL, 02 janv. 2024 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), un leader mondial des thérapies à base de cellules souches sanguines amplifiées, a annoncé aujourd'hui que ses hauts dirigeants tiendront des réunions d'investisseurs durant la 42e conférence annuelle J.P. Morgan Healthcare, du 8 au 11 janvier 2024, à San Francisco, en Californie, et participera aux conférences d’investisseurs suivantes en janvier :]]>https://www.globenewswire.com/news-release/2023/12/12/2794600/0/fr/ExCellThera-annonce-les-r%C3%A9sultats-positifs-des-%C3%A9tudes-de-phase-2-de-la-th%C3%A9rapie-cellulaire-UM171-chez-des-patients-atteints-de-leuc%C3%A9mies-et-de-my%C3%A9lodysplasies-%C3%A0-haut-risque-lors-du.html?f=22&fvtc=4&fvtv=48969ExCellThera annonce les résultats positifs des études de phase 2 de la thérapie cellulaire UM171 chez des patients atteints de leucémies et de myélodysplasies à haut risque lors du congrès annuel 2023 de l'American Society of Hematology (ASH)2023-12-12T12:00:07Z<![CDATA[- Données présentées lors d'une séance orale à l'ASH 2023, s'appuyant sur des données solides antérieures issues d'une étude de phase 1/2 et d'études comparatives de registres.]]>https://www.globenewswire.com/news-release/2023/12/12/2794600/0/en/ExCellThera-Announces-Positive-Phase-2-Study-Results-from-UM171-Cell-Therapy-in-Patients-with-High-risk-Leukemias-and-Myelodysplasias-at-American-Society-of-Hematology-ASH-2023-Ann.html?f=22&fvtc=4&fvtv=48969ExCellThera Announces Positive Phase 2 Study Results from UM171 Cell Therapy in Patients with High-risk Leukemias and Myelodysplasias at American Society of Hematology (ASH) 2023 Annual Meeting2023-12-12T12:00:07Z<![CDATA[- Data presented in an oral session at ASH 2023, building on strong data from prior Phase 1/2 trial and comparative registry studies]]>https://www.globenewswire.com/news-release/2023/11/03/2773160/0/en/ExCellThera-announces-new-UM171-data-to-be-presented-at-ASH-2023.html?f=22&fvtc=4&fvtv=48969ExCellThera announces new UM171 data to be presented at ASH 20232023-11-03T12:15:59Z<![CDATA[MONTREAL, Nov. 03, 2023 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and fitness, announced today several UM171 presentations, including an oral session on new data from Phase 2 studies of investigational UM171 cell therapy in high-risk blood cancer patients, at the 65th American Society of Hematology Annual Meeting & Exposition (ASH), taking place December 9-12, 2023, in San Diego, California. The abstracts are now available on the ASH website at www.hematology.org/meetings/annual-meeting/abstracts.]]>https://www.globenewswire.com/news-release/2022/12/12/2571866/0/en/UM171-cell-therapy-demonstrates-improved-outcomes-compared-to-cord-and-matched-unrelated-donor-peripheral-blood-transplants-in-real-world-setting.html?f=22&fvtc=4&fvtv=48969UM171 cell therapy demonstrates improved outcomes compared to cord and matched unrelated donor peripheral blood transplants in real-world setting2022-12-12T13:25:50Z<![CDATA[MONTRÉAL, Dec. 12, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy in a Phase 1/2 trial to those treated with cord blood and matched unrelated donor peripheral blood stem cell transplants. In this real-world analysis using matched-controlled data from the CIBMTR® (Center for International Blood and Marrow Transplant Research®), ECT-001 Cell Therapy demonstrated improved outcomes compared to cord blood (CB) and matched unrelated donor (MUD) peripheral blood stem cell (PBSC) transplants, including overall survival (OS), progression-free survival (PFS), and graft-versus-host disease (GVHD) and relapse-free survival (GRFS). The findings were presented yesterday in an oral session during the 2022 American Society of Hematology (ASH) Annual Meeting (Abstract #665).]]>https://www.globenewswire.com/news-release/2022/11/15/2556207/0/en/ExCellThera-announces-completion-of-Phase-2-clinical-trials-for-UM171-expanded-cell-therapy-in-high-risk-blood-cancers.html?f=22&fvtc=4&fvtv=48969ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers2022-11-15T13:32:40Z<![CDATA[MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its initial Phase 2 studies for high-risk leukemias and myelodysplastic syndromes (MDS). ECT-001 Cell Therapy, ExCellThera’s most advanced investigational drug, combines the proprietary molecule UM171 and an optimized culture system to produce unique UM171-expanded stem cell transplants, and it also enables the use of small cord blood units without compromising engraftment.]]>https://www.globenewswire.com/news-release/2022/11/08/2550973/0/en/ExCellThera-announces-100th-patient-treated-with-UM171-expanded-cell-therapy.html?f=22&fvtc=4&fvtv=48969ExCellThera announces 100th patient treated with UM171-expanded cell therapy2022-11-08T13:35:32Z<![CDATA[MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients. ECT-001 Cell Therapy is an investigational UM171-expanded cord blood cell therapy being evaluated in trials across multiple adult and pediatric hematological indications, including severe leukemias and myelodysplastic syndromes, in the United States and Canada. Additional clinical trials in Europe are expected soon.]]>https://www.globenewswire.com/news-release/2022/11/04/2548863/0/en/ExCellThera-announces-oral-presentation-of-new-data-on-UM171-expanded-cell-therapy-at-the-ASH-Annual-Meeting.html?f=22&fvtc=4&fvtv=48969ExCellThera announces oral presentation of new data on UM171-expanded cell therapy at the ASH Annual Meeting2022-11-04T13:30:57Z<![CDATA[MONTREAL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that an abstract related to ExCellThera’s most advanced investigational drug, ECT-001 Cell Therapy, has been accepted for oral presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 10-13, 2022. The abstract is now available on the ASH website at www.hematology.org.]]>https://www.globenewswire.com/news-release/2022/06/17/2464666/0/en/ExCellThera-announces-submission-of-Drug-Master-File-for-UM171.html?f=22&fvtc=4&fvtv=48969ExCellThera announces submission of Drug Master File for UM1712022-06-17T12:05:00Z<![CDATA[MONTRÉAL, June 17, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that it has submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for UM171, a proprietary molecule being studied for use in the expansion and rejuvenation of hematopoietic stem cells.]]>